

Please type a plus sign (+) inside this box → ☐ +

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0034


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED

FEB 25 2003

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/046,542	
	Filing Date	January 16, 2002	
	First Named Inventor	Wilfred Arthur Jefferies et al.	
	Group Art Unit	1632	
	Examiner Name	not available	
Total Number of Pages in This Submission	5	Attorney Docket Number	7685-41

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): (20) cited prior art references
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	BERESKIN & PARR
Signature	
Date	February 17, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#12
2/26/03

RECEIVED

FEB 5 2003

TECH CENTER 1600/2900

Our Reference No. 7885-4

RECEIVED
TECH CENTER 1600/2900
03 FEB 19 PM 3:17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
Wilfred Arthur Jefferies et al.)
)
Serial No. 10/046,542)
)
Filed: January 16, 2002)
)
For: Method of Enhancing an)
Immune Response)

Art Group Unit: 1632
Examiner: Unknown

The Commissioner of Patents & Trademarks
Washington, D.C. 20231
U.S.A.

Dear Sir:

FILING OF AN INFORMATION DISCLOSURE STATEMENT

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicants are aware. Applicants are also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language and accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column. Applicant reserves the right to contest the applicability of any of these documents as prior art against the subject application.


This Information Disclosure Statement is being filed within three months of the filing of the application or before the mailing date of a first Office Action on the merits; therefore, no fee is required.

If the Examiner has any questions concerning this Information Disclosure Statement, he is requested to contact the undersigned. If it is determined that this Information Disclosure Statement has been filed under the wrong rule, the Patent and Trademark Office is requested to consider this Information Disclosure Statement under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2095.

If additional fees are required, please charge the fees to our Deposit Account No. 02-2095.

Respectfully submitted,

Wilfred Arthur Jefferies et al.



Micheline Gravelle
Registration No. 40,261

Dated: February 17, 2003

Bereskin & Parr
Box 401, 40 King Street West
Toronto, Ontario
Canada M5H 3Y2

(416) 364-7311
Enclosures

Form PTO-1449 (REV. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 7685-41		SERIAL NO. 10/046,542	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANTS: Wilfred Jefferies et al.			
				FILING DATE January 16, 2002		GROUP 1632	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1.	Monaco, J.J., Immunology Today, Vol. 13, No. 5, May 1992, pages 173-179.					
	2.	Ossevoort, M.A. et al., European Journal of Immunology, Vol. 23, No. 12, 1993, pages 3082-3088					
	3.	Zweerink, H.J., et al., Journal of Immunology, Vol. 150, No. 5, March 1, 1993, pages 1763-1771.					
	4.	Arnold, D. et al., Nature, Vol. 360, No. 6400, November 12, 1992, pages 171-174.					
	5.	Momburg, F. et al., Nature, Vol. 360, No. 6400, November 12, 1992, pages 174-177.					
	6.	Kelly, A. et al., Nature, Vol. 355, No. 6361, February 13, 1992, pages 641-644.					
	7.	Spies, T. et al., Nature, Vol. 355, No. 6361, February 13, 1992, pages 644-646.					
	8.	Fruh, K. et al., Journal of Biological Chemistry, Vol. 267, No. 31, November 5, 1992, pages 22131-22140.					
	9.	Yang, Y. et al., Journal of Biological Chemistry, Vol. 267, No. 17, June 15, 1992, 11669-11672.					
	10.	Jefferies, W.A. et al., The Journal of Immunology, Vol. 151, No. 6, September 15, 1993, pages 2974-2985.					
	11.	Verma et al. (1997) Nature, vol. 389, 239-242, 1997.					
	12.	Miller et al. (1995) FASEB, vol. 9, 190-199, 1995.					
	13.	Spies et al. (1991) Nature, vol. 351, 323-324, May 1991.					
	14.	Momburg et al. (1992) Nature, vol. 360, 174-177, Nov. 1992.					
	15.	Franksson et al. (1993) J. Exp. Med., vol. 177, 201-205, Jan. 1993.					
	16.	Powis et al. (1991) Nature, vol. 354, 528-531, Dec. 1991.					
	17.	Bachmann et al. (1994) Current Opin. Immunol., vol. 6, 320-327, 1994.					
	18.	Restifo et al. (1993) J. of Experimental Medicine., vol. 177, 265-272, Feb. 1993.					
	19.	Orkin et al. (1995) "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", Dec. 1995.					
	20.	Gabathuler R. et al., The Journal of Experimental Medicine, Vol. 180, No. 4, October 1, 1994, pages 1415-1425					
EXAMINER:				DATE CONSIDERED:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

 RECEIVED
 FEB 25 2003
 TECH CENTER 1600/2900